| Assessment Status | Rapid Review Complete |
| HTA ID | 24010 |
| Drug | Epcoritamab |
| Brand | Tepkinly® |
| Indication | Epcoritamab (Tepkinly®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 11/03/2024 |
| Rapid review completed | 15/04/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of epcoritamab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/05/2024 |
| Pre-submission consultation with Applicant | 24/07/2024 |
| Full submission received from Applicant | 23/01/2025 |
Full submission withdrawn by the NCPE due to submission of commercial offer by the Applicant, July 2025.